Press "Enter" to skip to content

FDA issues warning letter for not including the most serious risks in advertisement for medication-assisted treatment drug

FDA issues warning letter to Alkermes, Inc., for misbranding the drug Vivitrol (an extended-release injection formulation of naltrexone) by omitting warnings about the most serious risks associated with the drug from promotional materials

Original source:

Also Read:   Maison Terre Issues Voluntary Nationwide Recall of Organic Goldenseal Root Powder Due to Microbial Contamination